In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Oncto Trac lung cancer imaging product will be distributed in North America by DuPont Radiopharmaceuticals under an agreement announced Oct. 6. NeoRx will receive $2 mil. from DuPont Merck upon signing of the contract and an additional $4.5 mil. upon FDA approval of the small-cell lung cancer imaging kit, as well as product royalties. DuPont Merck will receive 269,000 shares of NeoRx common stock. The imaging kit, manufactured by Boehringer Ingelheim's wholly owned subsidiary Dr. Karl Thamae GmbH, is currently under review for final approval by FDA's Center for Biologics Evaluation and Research



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts